Predicting a Biologic Treatment Fast-Responder Profile in Psoriatic Patients: Advanced Application of Artificial-Neural-Networks (ANNs)

Giovanni Damiani MD, Rosalynn R.Z. Conic MD PhD, Paolo D.M. Pigatto Prof MD, Carlo G. Carrera MD, Chiara Franchi MD, Angelo Cattaneo MD, Piergiorgio Malagoli MD, Radhakrishna Uppala Prof MD PhD, Dennis Linder Prof MD, Nicola L. Bragazzi MD PhD, Enzo Grossi Prof MD

The present study is possibly the first approach employing ANNs to predict drug efficacy in dermatology; a wider use of ANNs may be conducive to useful both theoretical and clinical insight.

Successful Management of a Black Male With Psoriasis and Dyspigmentation Treated With a Novel Combination .01%/.0045% Lotion: Case Report

Seemal R. Desai MD, Andrew F. Alexis MD MPH, Abby Jacobson MS PA-C

Skin of color patients with psoriasis face unique challenges related to disease characteristics and treatment. Dyspigmentation, including postinflammatory hypo- and hyperpigmentation, more frequently and severely affects patients with skin of color and remains a challenge in psoriasis management. We present the case of a 58-year-old Black male with moderate psoriasis who was treated for 8 weeks with a fixed combination novel 0.01%/0.045% lotion during a phase 3 study (NCT02462070).

Topical Cannabinoids for the Management of Psoriasis Vulgaris: Report of a Case and Review of the Literature

Adam J. Friedman MD, Kimia Momeni BS, Mikhail Kogan MD

The interest in use of medical cannabis for chronic dermatologic conditions such as psoriasis, eczema, and acne has been growing mostly owing to rapidly emerging decriminalization across the country and impressive commercially driven popularization of a variety of cannabinoid preparations including topical forms such as creams, salves, lotions, lubricants, and many others. We present a case of a young man with psoriasis managed with topical cannabinoids.

Tumor Necrosis Factor Inhibitor-Induced Psoriasis in a Pediatric Crohn’s Disease Patient Successfully Treated with Another Biologic

Lauren Bonomo , Ellen H. de Moll , Linden Li , Lauren Geller , Michael I. Gordon , David Dunkin

This is the first reported case of a school-age pediatric patient with TNF inhibitor-induced psoriasis treated with another biologic. Controlled trials are warranted to fully assess the safety and efficacy of this biologic for treating TNF inhibitor-induced psoriasis in the pediatric population.

Is TNF-α Inhibitor-Induced Psoriasiform Dermatitis Always Psoriasiform?

Chapman Wei BS, Emily C Murphy MD, Joseph Zahn MD, Adam J. Friedman MD FAAD

Based on the mounting evidence in the literature that TNFI-induced ‘psoriasiform’ eruptions present with a wide spectrum of overlapping morphology and histopathologic features, the characterization of TNFI-induced lesions should rely more on the histopathologic pattern.

Rapid and Sustained Improvement in a Patient With Plaque Psoriasis Switched to Brodalumab After Failing Treatment Clearance on Six Other Biologic Therapies

Kathleen Haycraft DNP, Linda Cooke MD

Psoriasis is a chronic, inflammatory, remitting/relapsing autoimmune condition involving a dysregulated inflammatory response of the interleukin (IL) 23/T-helper (Th)-17 pathway. Greater understanding of the immune-mediated pathology of the disease has led to the development of numerous biological therapies and biosimilars that target the various inflammatory pathways.

Successful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Novel Biologic Combination Therapy: A Case Report

Dipali Rathod DNB DDVL, Jeffrey M. Weinberg MD, Paul S. Yamauchi MD, Leon H. Kircik MD, Uwe Wollina MD, Torello Lotti MD, Mohamad Goldust MD

There is limited data supporting the combination of biological agents in the management of psoriasis and psoriatic arthritis. This is the first case report of plaque psoriasis with arthritis, successfully treated with two biologic combination therapy, without concurrent use of other systemic agents during the treatment. However, further studies need to be carried out to evaluate the efficacy and safety of this biologic combination therapy.

Ostraceous Psoriasis Presenting as Koebner Phenomenon in a Tattoo

Jacob Reinhart MD, Matthew Willett MD, Neil Gibbs MD

Psoriasis is a common dermatologic condition with a variety of morphologic presentations. These variations include the less common hyperkeratotic form, psoriasis ostracea, defined as having pronounced adherent scales resembling an oyster shell. Of the ostraceous cases that have been reported in the literature, many occur as generalized outbreaks in patients with long-standing history of psoriasis. Rarely does this remarkable variant occur as a direct flare from a cutaneous insult. In these situations, when a pre-existing dermatosis appears in response to a traumatic insult to skin, the process is referred to as the Koebner phenomenon.

Psoriasiform Pemphigus Foliaceus in an African American Female: An Important Clinical Manifestation

Evan Austin BS, Jillian W. Millsop MD, Haines Ely MD, Jared Jagdeo MD MS, and Joshua M. Schulman MD

A 50-year-old African-American woman presented to the dermatology clinic with a pruritic eruption of 3 years’ duration. On clinical examination, the patient had well-demarcated, pink, atrophic plaques and superficial erosions over the inframammary folds and mid-chest. She also had well-demarcated, hyperpigmented, hyperkeratotic scaly plaques over the abdomen, suprapubic region, elbows, knees, and back with sporadic small superficial blisters.